Recursion to Report First Quarter 2026 Business Updates and Financial Results on May 6
Rhea-AI Summary
Recursion (Nasdaq: RXRX) will report first quarter 2026 business updates and financial results on Wednesday, May 6, 2026, before market open. The company will host a public Earnings Call at 8:00 am ET / 6:00 am MT / 1:00 pm BST and stream live on Recursion's X, LinkedIn, and YouTube accounts. Investors may submit questions via the company form link provided.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – RXRX
On the day this news was published, RXRX declined 3.23%, reflecting a moderate negative market reaction. Argus tracked a peak move of +2.4% during that session. Our momentum scanner triggered 17 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $63M from the company's valuation, bringing the market cap to $1.89B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
RXRX declined 2.01% while several biotech peers like GLPG, APGE, ARQT, IDYA, and TVTX also showed negative moves, indicating pressure across related names despite the scanner not flagging broad momentum.
Previous Earnings date Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 18 | Earnings date notice | Neutral | +2.0% | Set expectations for Q4 and full‑year 2025 results and call logistics. |
Prior earnings date news led to a modest positive move of 2.02%, suggesting the market has reacted constructively to scheduling announcements.
Over the past months, Recursion has highlighted its AI‑driven platform, clinical progress, and active investor engagement. The company reported Q4 and full‑year 2025 results with clinical validation of its AI OS, milestone receipts, and cash of $754 million, which saw a 6.8% move. Conference participation and leadership changes, including a new CMO, had relatively muted price impacts. The prior earnings date notice on Feb 18, 2026 produced a 2.02% gain. Today’s announcement fits this pattern of pre‑scheduled communication around results and business updates.
Historical Comparison
In the past 6 months, RXRX issued 1 prior earnings date notice, which saw an average move of 2.02%. This context frames how the market has historically reacted to similar scheduling updates.
Earnings communications have followed a consistent pattern: announcing dates ahead of results and hosting public calls with live streams and pre‑submitted questions.
Market Pulse Summary
This announcement schedules Recursion’s first quarter 2026 results for May 6, 2026, with a public earnings call at 8:00 am ET streamed across major platforms and open to submitted questions. Historically, similar earnings date notices produced a modest 2.02% move, while the actual Q4 and full‑year 2025 report saw a stronger 6.8% reaction. Investors may focus on how Q1 metrics and business updates build on that prior report and whether they affect the stock’s position below the 200‑day MA.
AI-generated analysis. Not financial advice.
Company to host public Earnings Call on May 6 at 8:00 am ET / 6:00 am MT / 1:00 pm BST
Salt Lake City, UT, April 29, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business updates and report its first quarter 2026 financial results on Wednesday, May 6, 2026, before the open of the financial markets.
Recursion will host an Earnings Call on May 6, 2026 at 8:00 am ET / 6:00 am MT / 1:00 pm BST. The company will broadcast the live stream from Recursion’s X, LinkedIn, and YouTube accounts. Investors, analysts, and the public will be able to ask questions of the company by submitting questions here: https://forms.gle/TQ4vgUTLKsFmikcu6.
About Recursion
Recursion (NASDAQ: RXRX) is a clinical stage TechBio company decoding biology to radically improve lives. Recursion is advancing a portfolio of differentiated investigational medicines across its wholly owned and partnered pipeline in oncology, rare disease, neuroscience, immunology, and other therapeutic areas with significant unmet need. Enabling its mission is the Recursion OS, an AI-native, end-to-end drug discovery and development platform integrating biology, chemistry, and clinical development into a unified intelligence system. Powered by proprietary multimodal data, purpose-built AI models, and bilingual teams fluent in both science and AI, the Recursion OS is designed to translate complex science into medicines that matter — faster, better, and at scale — for patients who are waiting.
Recursion’s platform infrastructure is anchored in Salt Lake City, Utah and Milton Park, Oxfordshire, where its automated biology and chemistry laboratories generate proprietary data at industrial scale. Recursion also maintains offices in New York, Montréal, and London, three global hubs for talent and leadership at the intersection of AI and scientific innovation. Learn more at www.recursion.com, or connect on X and LinkedIn.
Forward-Looking Statements
This document contains information that includes or is based upon “forward-looking statements” within the meaning of the Securities Litigation Reform Act of 1995, including, without limitation, those regarding the timing of the filing of quarterly earnings; the occurrence and timing of an investor call; early and late stage discovery, preclinical, and clinical programs; licenses and collaborations; prospective products and their potential future indications and market opportunities; Recursion OS and other technologies; business and financial plans and performance; and all other statements that are not historical facts. Forward-looking statements may or may not include identifying words such as “plan,” “will,” “expect,” “anticipate,” “intend,” “believe,” “potential,” “continue,” and similar terms. These statements are subject to known or unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements, including but not limited to: challenges inherent in pharmaceutical research and development, including the timing and results of preclinical and clinical programs, where the risk of failure is high and failure can occur at any stage prior to or after regulatory approval due to lack of sufficient efficacy, safety considerations, or other factors; our ability to leverage and enhance our drug discovery platform; our ability to obtain financing for development activities and other corporate purposes; the success of our collaboration activities; our ability to obtain regulatory approval of, and ultimately commercialize, drug candidates; our ability to obtain, maintain, and enforce intellectual property protections; cyberattacks or other disruptions to our technology systems; our ability to attract, motivate, and retain key employees and manage our growth; inflation and other macroeconomic issues; and other risks and uncertainties such as those described under the heading “Risk Factors” in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. All forward-looking statements are based on management’s current estimates, projections, and assumptions, and Recursion undertakes no obligation to correct or update any such statements, whether as a result of new information, future developments, or otherwise, except to the extent required by applicable law.
Media Contact media@recursion.com Investor Contact investor@recursion.com